Foley Represents Alpha IRB in Sale to Sabai Group

Foley & Lardner LLP served as legal advisor to Alpha Independent Review Board, LLC (“Alpha IRB”) in its sale to Sabai Group LLC (“Sabai”).

Founded in 2007 and headquartered in San Clemente, CA, Alpha IRB specializes in ethical review and human research protections through AAHRPP-accredited IRB services for clinical trial sponsors, CROs, sites, and institutions. Alpha IRB’s bench of talented IRB professionals and board members has deep experience in growing therapeutic areas that complement not only Sabai’s existing IRB capabilities, but also its Institutional Biosafety Committee (“IBC”) and cell-gene therapy focused service offerings. Founder and CEO of Alpha IRB, Marianne Thornton, has joined Sabai’s Board of Directors.

Sabai specializes in custom solutions for biosafety and human research protections through IRB, IBC, and consulting services. Headquartered in Chesterfield, MO, Sabai’s biosafety and ethical review experts have supported their biotech, pharma, and device partners since 2017.

The Foley deal team was led by partner Susan Pravda and senior counsel Alexander Miska and included associate Ryan McNulty with support from partners Nathan Beaver, Krista Cabrera, Monica Chmielewski, Chanley Howell, Casey Knapp, Ethan Lenz, Christopher McKenna, John Palmer, and senior counsel Sonia Kothari.